Advertisement

Annals of Nuclear Medicine

, Volume 33, Issue 4, pp 223–236 | Cite as

4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research

  • Kiichi IshiwataEmail author
Open Access
Review Article
  • 331 Downloads

Abstract

4-10B-Borono-2-18F-fluoro-l-phenylalanine (18F-FBPA) was developed for monitoring the pharmacokinetics of 4-10B-borono-l-phenylalanine (10B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The tumor-imaging potential of 18F-FBPA was demonstrated in various animal models. Accumulation of 18F-FBPA was higher in melanomas than in non-melanoma tumors in animal models and cell cultures. 18F-FBPA was incorporated into tumors mediated mainly by L-type amino acid transporters in in vitro and in vivo models. Tumoral distribution of 18F-FBPA was primarily related to the activity of DNA synthesis. 18F-FBPA is metabolically stable but is incorporated into melanogenesis non-enzymatically. These in vitro and in vivo characteristics of 18F-FBPA corresponded well to those of 10B-BPA. Nuclear magnetic resonance and other studies using non-radioactive 19F-10/11B-FBPA also contributed to characterization. The validity and reliability of 18/19F-FBPA as an in vivo probe of 10B-BPA were confirmed by comparison of the pharmacokinetics of 18F-FBPA and 10B-BPA and direct measurement of both 18F and 10B in tumors with various doses of both probes administered by different routes and methods. Clinically, based on the kinetic parameters of dynamic 18F-FBPA PET, the estimated 10B-concentrations in tumors with continuous 10B-BPA infusion were similar to those measured directly in surgical specimens. The significance of 18F-FBPA PET was verified for the estimation of 10B-concentration and planning of BNCT. Later 18F-FBPA PET has been involved in 10B-BPA BNCT of patients with intractable tumors such as malignant brain tumors, head and neck tumors, and melanoma. Usually a static PET scan is used for screening patients for BNCT, prediction of the distribution and accumulation of 10B-BPA, and evaluation of treatment after BNCT. In some clinical trials, a tumor-to-normal tissue ratio of 18F-FBPA > 2.5 was an inclusion criterion for BNCT. Apart from BNCT, 18F-FBPA was demonstrated to be a useful PET probe for tumor diagnosis in nuclear medicine: better tumor-to-normal brain contrast compared with 11C-methionine, differentiation of recurrent and radiation necrosis after radiotherapy, and melanoma-preferential uptake. Further progress in 18F-FBPA studies is expected for more elaborate evaluation of 10B-concentrations in tumors and normal tissues for successful 10B-BPA BNCT and for radiosynthesis of 18F-FBPA to enable higher 18F-activity amounts and higher molar activities.

Keywords

18F-FBPA 10B-BPA PET BNCT Malignant tumor 

Abbreviations

BBB

Blood–brain barrier

BNCT

Boron neutron capture therapy

10B-BPA

4-10B-Borono-l-phenylalanine

BSH

Sodium 10B-borocaptate

18F-FBPA

4-10B-Borono-2-18F-fluoro-l-phenylalanine

ICP–AES

Inductively coupled plasma–atomic emission spectroscopy

ICP–MS

Inductively coupled plasma–mass spectroscopy

LAT

L-type amino acid transporter

MR

Magnetic resonance

PET

Positron emission tomography

Pulsed-HIFU

Pulsed high-intensity focused ultrasound

SUV

Standardized uptake value

T/B

Tumor-to-normal brain

T/N

Tumor-to-normal tissue

Introduction

Boron neutron capture therapy (BNCT) is a radiotherapeutic technique that selectively treats tumor cells with high-energy α particles and recoiling 7Li nuclei via 10B(n,α)7Li produced by the neutron irradiation of 10B-containing compounds located selectively in tumor tissues. The preferential characteristics of boron delivery agents for BNCT comprise high tumor uptake for several hours, relatively rapid clearance from blood and normal tissues, and low toxicity. So far, only two 10B-compounds have been used clinically, sodium 10B-borocaptate (Na2BI2H11SH or BSH) and 4-10B-borono-l-phenylalanine (10B-BPA), although a large number of 10B-compounds have been synthesized for over 50 years [1, 2, 3, 4]. 10B-BPA is taken up by tumor tissues mainly by an L-type amino acid transporter (LAT), whereas BSH lacks such a tumor-specific uptake system and is taken into tumors by diffusion. To date, 10B-BPA appears to be in greater use in early clinical trials because of its very low toxicity and differential target/non-target extraction. It has been noted, however, that neither of these two agents, the so called second-generation boron-delivery agents, adequately fulfill the criteria required for BNCT and that third-generation agents are under development [2, 3, 4].

10B-BPA was originally synthesized as a possible 10B-boron-containing agent aimed at BNCT by Synder et al. [5]. Mishima et al. investigated 10B-compounds involved in melanogenesis, and applied 10B-BPA to a patient with malignant melanoma in BNCT for the first time [6]. Coderre et al. demonstrated that 10B-BPA could be applied to other tumors in experimental models: KHJJ murine mammary tumor, GS-9L rat glioma, and human U-87 MG glioma xenograft [7]. For successful BNCT in patients with malignant tumors, in vivo evaluation of the pharmacokinetics of 10B-BPA is one such problem that still needs to be resolved. 4-10B-Borono-2-18F-fluoro-l-phenylalanine (18F-FBPA) was developed in 1991 as a positron emission tomography (PET) probe for imaging and the evaluation of the pharmacokinetics of 10B-BPA in vivo [8]. After several characterization studies of 18F-FBPA using animal models in the early 1990s [8, 9, 10, 11, 12], 18F-FBPA PET has been clinically applied [13, 14, 15, 16, 17, 18, 19], and the significance of 18F-FBPA PET in BNCT using 10B-BPA has been established [1, 2, 3, 4, 20, 21, 22, 23]. However, 18F-FBPA PET has expanded to only limited numbers of PET facilities, mainly because BNCT is performed in a small number of institutes with nuclear reactors as a neutron source for BNCT. The problem of suitable reactors being located outside of hospitals makes clinical trials of BNCT very difficult. To overcome this problem, accelerator-based neutron sources for BNCT in the hospital were proposed [24], and the development of such accelerators is progressing [25]. Recently, a cyclotron that generates an epithermal-neutron source for BNCT was developed [23, 26, 27], and phase I and II clinical trials of BNCT using this cyclotron are progressing in Japan. Together with these sources of progress, further basic and clinical studies on 18F-FBPA aimed for BNCT have been reported in recent years.

Many reviews of BNCT including clinical studies of 18F-FBPA PET have been published; however, reviews focusing on 18F-FBPA PET, especially basic studies of 18F-FBPA, are limited in number [20, 21, 22, 23]. Furthermore, in addition to BNCT, the usefulness of 18F-FBPA PET in the general diagnosis of tumors was also reported. This review summarizes basic and clinical studies on 18F-FBPA during the last quarter century, focusing on PET radiopharmaceutical science. Regarding basic research, the findings using non-radioactive 19F-FBPA and related 10/11B-BPA are also covered.

Radiosynthesis of 18F-FBPA

18F-FBPA was synthesized by electrophilic substitution of 10B-BPA using carrier-added 18F–F2 produced via three routes (Fig. 1). First, carrier-added 18F–F2 was produced using the 20Ne(d,α)18F nuclear reaction and converted to 18F-acetylhypofluorite [8]. For this production an in-house cyclotron with a relatively large deuteron beam energy (about 8 MeV and more) is required, but the activity yields of 18F–F2 are limited. Consequently, the activity amount and molar activities of 18F-FBPA were very low: 440–1200 MBq and 20–130 MBq/µmol, respectively [8, 17, 28, 29]. It was noticed that the first synthesis was done by fluorination of racemic BPA [8]. Recently this route was re-examined in detail for the reliable production of 18F-FBPA for routine clinical use [30]. The formulation process of 18F-FBPA is available in the other syntheses, as described below. In this synthesis, the d-isomer of 18F-FBPA and contamination by trifluoroacetic acid used as a reaction solvent were confirmed to be negligible for the first time.

Fig. 1

Radiosynthesis of 4-10B-borono-2-18F-fluoro-l-phenylalanine (18F-FBPA). The electrophilic substitution of 10B-BPA with 18F-acetylhypofluorite (18F-AcOF) and 18F–F2 produced 18F-FBPA as a predominant product, 4-10B-borono-3-18F-fluoro-l-phenylalanine as a minor product, and 2-, 3-, and 4-fluoro-l-phenylalanine as byproducts. 18F-AcOF is considered to have a higher selectivity compared to 18F–F2

To obtain greater activity amounts of 18F–F2 and resulting relatively high molar activities, a second route for the production of 18F–F2 using the 18O(p,n)18F nuclear reaction with 18O–O2 [31] and 18O–H2O was devised [32]. This 18F–F2 can be produced using even a small proton-only accelerator. Thus, the activity yields of 18F-FBPA were improved greatly: 2000–5300 MBq [19, 33 (seemed to use BPA containing naturally abundant 10/11B-boron for 18F-FBPA synthesis)]. The third route using 18O–H2O-derived 18F–F2 achieved the highest molar activity 3700 MBq/µmol, but the activity yield of 18F-FBPA did not seem to be improved [34, 35].

18F-FBPA synthesis via the second and third routes may be referred to as the second-generation methods. Many people anticipate the feasibility of the third-generation synthesis of 18F-FBPA by nucleophilic fluorination using no-carrier-added 18F-fluoride produced using the 18O(p,n)18F nuclear reaction. The method could hopefully achieve a high activity amount and high molar activity of 18F-FBPA as the synthesis of 18F-FDG [36], but this has not yet been established.

Experimental studies in in vitro and in vivo models

Tumor accumulation of 18F-FBPA and PET imaging

In the 1990s, based on the clinical interest of Mishima and co-workers who applied 10B-BPA BNCT for patients with malignant melanoma [6], Ishiwata et al. demonstrated the potential of tumor accumulation of 18F-FBPA in mice with B16 melanoma and non-melanoma FM3A mammary carcinoma [9, 10] and in hamsters with Greene’s melanomas: melanotic no. 179 and amelanotic no. 178 [10, 11]. The accumulation of 18F-FBPA in these tumor models was evaluated using ex vivo γ-counting after tissue dissection. The ability of melanogenesis in tumors enhanced the uptake of 18F-FBPA. In a hamster model, melanotic no. 179 showed a 1.7-times higher uptake of 18F-FBPA than amelanotic no. 178, although both melanomas had similar metabolic activities when examined using a tracer uptake study with l-14C-methionine, 2-deoxy-d-14C-glucose and 3H-thymidine, which mainly reflect protein synthesis, glucose metabolism and DNA synthesis, respectively [10, 11]. In the mouse model, B16-F10 melanoma, which has a more highly metastatic potential and a more rapid growing rate but lower melanin content, showed lower uptake of 18F-FBPA than B16-F1 melanoma. These findings were explained by the fact that 18F-FBPA was partially incorporated in melanogenesis (see the section on the “Metabolism of 18F-FBPA”). Later, compared with non-melanoma cells, a higher uptake of 18F-FBPA in melanoma cells was also observed in vitro [37]. Prior these studies Coderre et al. reported a higher uptake of 10B-BPA in Harding–Passey melanoma than in the non-melanoma (mammary adenocarcinoma) in mice [38]. Ishiwata et al. used racemic 18F-FBPA in initial works [8, 9, 10], although it was known that the L-form of BPA was preferentially accumulated compared with the d-isomer [7]. Therefore, they further clarified that uptake of the L-form of 18F-FBPA was higher than that of the d-form in B16 melanoma [11]. Recently, similar findings were confirmed in C6 glioma-bearing rats [39].

The heterogeneous distribution of 18F-FBPA in tumor tissues was visualized ex vivo by whole-body autoradiography of mice with B16 melanoma or FM3A mammary carcinoma [9, 10]. Later, 10B-boron distribution in the tumors after injection of 10B-BPA was visualized ex vivo directly by neutron capture autoradiography using CR-39 nuclear track detectors [40].

In the 2000s, as technology advanced, PET imaging of 18F-FBPA in animal models was performed using high-spatial resolution PET scanners developed for small animals, although the first PET imaging was demonstrated in Greene’s melanoma-bearing hamsters with 8 mm of spatial resolution [11]. From a clinical interest in BNCT for patients with malignant brain tumors, Chen et al. performed a pilot study estimating the kinetic parameters of 18F-FBPA in F98-glioma-bearing rats using a PET apparatus with a spatial resolution of around 1.6 mm [41]. They measured quantitatively the forward (K1) and reverse transport rates (k2) of 18F-FBPA across the blood–brain barrier (BBB) and the anabolic (specific binding to the target) (k3) and reverse processes (k4) in tumor tissues based on a modified three-compartment physiological model [17, 18] (see the section on the “Assessment of 10B with 18F-FBPA-PET for l-BPA BNCT”). They found that tracer uptake capacity depends on K1, like in observed clinical studies [17, 18]. Later, it was confirmed that K1 is mediated mainly by LAT, especially LAT-1, in vitro and in vivo as described below [42, 43] (see the section on the “Transport of 18F-FBPA”).

Regarding in vivo imaging of FBPA, Porcari et al. reported that 19F magnetic resonance (MR) imaging of racemic 10B-enriched 19F-FBPA was an alternative technique to the monitoring of 10B-BPA [44]. Using a 7T MR-scanner they showed high accumulation of 19F-FBPA in C6 glioma in the rat brains, for which the images were superimposed on T2-weighted spin echo axial 1H images, after infusion of 19F-FBPA (300 mg/kg, no toxicity was confirmed) through the carotid artery. The signal-to-noise of each 19F MR image indicated the highest concentration of 19F at 2.5 h after infusion, and the concentration decreased gradually. Furthermore, quantitative 19F MR spectroscopic measurements of blood from the femoral vein show that the concentration of the total fluorinated compound decreases by approximately 22% from 1 to 2.5 h after infusion and then it remains constant until 4 h after infusion.

It is notable that MR imaging has been applied to other boron containing agents such as BSH [1, 45]. Both 10B and 11B are detectable by MR technique. 11B displays a higher sensitivity and better spectral resolution than 10B. However, the longer T2 relaxation time of 10B has a detection advantage. The possibility of the 11B MR imaging of BNCT agents in vivo in a dog and a patient with glioblastoma multiforme treated with BSH [46] and in a Fischer rat treated with Na4B24H22S21 has been documented [47]. Bendel et al. demonstrated the 10B MR imaging of 10B-enriched BSH in mice bearing M2R melanoma xenografts, and estimated boron concentration in kidney [48]. Further studies of MR imaging of boron agents including BPA are being conducted, but are beyond the scope of this review.

In the 2010’s several investigators using animal models bearing human cancer xenografts and high-spatial resolution PET scanners, visualized a heterogeneous distribution of 18F-FBPA in the tumor [40, 49], and performed further biological studies as described below.

Cellular distribution of 18F-FBPA

The cellular distribution of 18F-FBPA in mice bearing two B16 melanoma sublines and FM3A mammary carcinoma was investigated using double-tracer microautoradiography [12]. The greatest amount of 18F-FBPA was observed in S phase melanocytes and the lowest amount was found in non-S phase non-melanocytes. 18F-FBPA accumulation was primarily related to the activity of DNA synthesis, as evaluated using [3H]thymidine, and secondarily to the degree of pigmentation in melanocytes. Prior to this study, Coderre et al. compared the tumoral distribution of 10B-BPA (neutron capture radiography) and 3H-thymidine (autoradiography) in Harding–Passey melanoma bearing mice. They found that the highest concentrations of l-BPA in the tumor corresponded closely with areas with high 3H-thymidine incorporation [38]. Notably, Bailey et al. found using flow cytometry that 24–72-h exposure to racemic FBPA increased the incorporation of bromodeoxyuridine into glioblastoma cells, suggesting that FBPA might directly affect the DNA synthetic pathway of tumor cells [50]. They considered that the previously reported increase of incorporation of FBPA in DNA synthesizing cells [12, 38] may actually reflect the action upon the DNA synthetic pathway of target cells.

Using human glioblastoma T98G cells, Chandra et al. visualized the cellular distribution of 19F-10/11B-FBPA prepared from l-BPA containing naturally abundant boron (80 atom% 11B, 20 atom% 10B) and 10B-BPA (> 95 atom% 10B) at the same dose using ion microscopy coupled with confocal laser scanning microscopy [secondary ion mass spectroscopy imaging] [51]. The mitochondria-rich perinuclear cytoplasmic region exhibited significantly lower 19F-fluorine and 11B-boron signals than the remaining cytoplasm and the nuclei, and ion microscopy observations revealed a nearly 1:1 distribution of 19F-fluorine and 11B-boron in subcellular compartments. This finding suggested that defluorination or decomposition of 19F-FBPA did not occur in tumor cells. No significant difference in the cellular localization of 11B-boron or 10B-boron was observed between the 19F-10/11B-FBPA and 10B-BPA.

Tumor imaging potential of 18F-FBPA compared with other PET probes

The tumor imaging potential of 18F-FBPA was compared with other PET probes. Tumor uptake of racemic 18F-FBPA was similar to that of 11C-methionine in FM3A mammary carcinoma bearing mice [9]. In F98-glioma-bearing rats, tumor uptake of 18F-FBPA was lower than that of another artificial 18F-labeled amino acid derivative, O-2-18F-fluoroethyl-l-tyrosine, but the tumor-to-normal brain (T/B) ratios were rather higher [52]. Tumor uptake of 18F-FDG was much higher than that of these two 18F-labeled amino acids when dissecting tissues and measuring using γ-counter; however, the high uptake of 18F-FDG in the normal brain gave blurred brain tumor images. Watabe et al. compared 18F-FBPA, 11C-methionine, and 18F-FDG in a rat xenograft model of C6 glioma [42]. Tumor uptake values of 18F-FBPA and 11C-methionine were similar and lower than that of 18F-FDG, whereas the uptake values of 18F-FBPA and 11C-methionine in turpentine oil-induced inflammatory lesions were significantly lower than that of 18F-FDG. These findings suggested the usefulness of 18F-FBPA and 11C-methionine for differentiating between tumor and inflammation; however, differences in tumor-to-inflammatory lesion uptake ratios were not especially large in this model: 18F-FBPA, 1.7; 11C-methionine, 2.1; and 18F-FDG, 1.6.

Transport of 18F-FBPA

Wittig et al. reported that 10B-BPA is transported in rat 9L gliosarcoma cells and Chinese hamster V79 cells by a LAT based on the findings for 10B-BPA import and efflux measurements in the presence of system L- and system A-specific substrates [53]. Among the system L family, particularly LAT-1, which is highly expressed in malignant tumors, may play a major role in the effectiveness of 10B-BPA in BNCT [54]. Wongthai et al. evaluated the subtype specificity. Km values of 10B-BPA for ATB0,+, LAT-1 and LAT-2 (mainly expressed in normal tissues) were 137, 20, and 88 µM (LAT-2/LAT-1 = 4.3), respectively [55].

Regarding the transport of 18F-FBPA, Yoshimoto et al. found that 18F-FBPA was incorporated mainly into three human glioblastoma cell lines (74.5–81.1% of total uptake), by LAT [43]. 18F-FBPA uptake was decreased dose-dependently to 2.1–7.1% of control by 1 mM 10B-BPA. They also found that the contribution of LAT to 14C-methionine uptake was 48.3–59.4%, and suggested that 11C-methionine PET might overestimate the concentration of 10B-BPA in tumor tissues. Watabe et al. [42] also demonstrated that 18F-FBPA uptake was specific for LTA-1 in human embryonic kidney 293 cells (HEK293). Km values of 18F-FBPA for LAT-1 and LAT-2 (normal cell type transporter) were 197 and 2810 µM (LAT-2/LAT-1 = 14), respectively. These findings suggested that 18F-FBPA is more specific for LAT-1 than 10B-BPA [55] and that 18F-FBPA is taken up less by tumor and normal tissues than 10B-BPA. The tumor-to-normal tissue (T/N) ratios of 18F-FBPA PET may be different from those of 10B-BPA in BNCT.

Metabolism of 18F-FBPA

Metabolic pathways of 18F-FBPA are summarized in Fig. 2 based on the results of early animal studies [9, 10]. In general, it is considered that the artificial amino acids are not incorporated into proteins. In non-melanoma FM3A mammary carcinoma, most 18F-activity was detected as 18F-FBPA over 6 h post injection, and the protein-binding fraction was negligible, whereas in B16 melanoma considerable amount of 18F-activity were detected in the protein-binding fraction (27% by 6 h), suggesting the involvement of 18F-FBPA in melanogenesis, as shown using double-tracer microautoradiography above [12]. On the other hand, the protein-binding fraction in plasma increased with time after injection of 18F-FBPA [9]. This finding suggested the deboronation of 18F-FBPA in vivo. In the liver, phenylalanine 4-monooxygenase may convert 18F-FBPA to 2-18F-fluoro-l-tyrosine, which was used in the synthesis of plasma proteins secreted into the blood stream [56]. Even if 2-18F-fluoro-l-tyrosine is re-circulated from the liver into the blood stream, it may make only a minor contribution to the total 18F-activity in tumor tissues. These findings suggested a slight discrepancy between the concentrations of 18F-activity and 10B in the animal studies to a certain extent, as described below. Regarding the metabolic change of BPA, Bendel et al. reported that the borate group was partly cleaved from BPA in the 10B MR analysis of human urine samples periodically collected from patients with head and neck squamous cell carcinoma [57].

Fig. 2

Metabolism of 18F-FBPA in C3H/He mice bearing FM3A mammary carcinoma and C57BL/6 mice bearing B16 melanoma. Transport of 18F-FBPA from plasma to the tumor and liver is mainly mediated by L-type amino acid transporter (LAT)-1 and − 2, respectively. Negligible protein-bound 18F-activity was found in FM3A mammary carcinoma [9]. 18F-2-Fluoro-l-phenylalanine (18F-FPhe) was not detected but speculated from an increasing protein-bound fraction of 18F-activity in plasma: 20% at 2 h in C3H/He mice [10] and 33% at 6 h in C57BL/6 mice [11]. The protein-bound fraction of 18F-activity (27% at 6 h) in B16 melanoma was evaluated as 18F-melanin [10]

No further studies on the metabolism of 18F-FBPA have been reported except for the work of Grunewald et al., in which plasma metabolites were analyzed for kinetic analysis of 18F-FBPA PET in tumor-bearing mice (> 96% unchanged 18F-FBPA in plasma at 60 min post injection) [58]. Clinically, three groups confirmed unchanged 18F-FBPA to be > 94% in plasma up to 50 min in dynamic 18F-FBPA PET [17, 34, 59], suggesting that 18F-FBPA is stable in humans at least as measured by PET.

Validity and reliability of 18F-FBPA as a 10B-BPA probe

Several studies have indicated that FBPA and 10B-BPA exhibit similar pharmacokinetics and that 18F-FBPA can become an in vivo probe to monitor the behavior of 10B-BPA. Ishiwata et al. compared the 10B concentrations estimated by two methods in B16 melanoma-bearing mice and Greene’s melanoma-bearing hamsters after intravenous injection of a mixture of 18F-FBPA (1.0–2.6 mg/kg) and 10B-BPA (14–80 mg/kg) [11]. First, 10B derived from both 18F-FBPA and 10B-BPA was measured directly by inductively coupled plasma atomic emission spectroscopy (ICP–AES). Second, 10B was calculated from 18F-activity measured ex vivo using γ-counter and the molar activities that were determined as the 18F-activity per summed mass of 18F-FBPA and 10B-BPA based on the hypothesis that 18F-FBPA and 10B-BPA behave as the same compound in vivo. The 10B concentrations calculated from 18F-activity were comparable with those measured by ICP–AES in Greene’s melanoma but much lower in B16 melanoma. The discrepancy was larger in blood and muscle. The findings indicated that the 18F-FBPA was useful as an in vivo probe of 10B-BPA, although species or tissue differences exist to a certain degree between 18F signals and 10B concentrations.

Wang et al. showed that the time courses of 10B-BPA and 18F-FBPA measured ex vivo by ICP–MS and γ-counting, respectively, were similar in F98 glioma and normal brain with maximal levels at 1 h, when different doses of 18F-FBPA (0.5–0.8 mg/kg, estimated by the author) and 10B-BPA (172 mg/kg) were separately injected into two groups of F98 glioma-bearing rats [28]. However, a certain discrepancy was again observed between T/B ratios of 10B concentration in the two groups and between T/B ratios of 10B and those of 18F in rats given 18F-FBPA.

After these early studies, Hanaoka et al. performed dynamic whole-body PET/CT scans for 1 h in RGC6 glioma-bearing rats after intravenous injection of 18F-FBPA (1.7 mg/kg), and 1 h later the same rats were given intravenous injection of 10B-BPA (18.7 mg/kg), and found a significant positive correlation between the accumulation levels of 18F-FBPA and 10B-BPA measured ex vivo by ICP–MS in blood and in ten tissues including tumors in RGC6 glioma-bearing rats [29]. The group estimated the 10B concentrations using a practical formula [60]:
$$^{{10}}{\text{B}}\;{\text{ppm}}\,=\,0.0478\, \times \,1\;{}^{0}{\text{B-BPA}}\;{\text{dose}}\;\left( {{\text{mg}}/{\text{kg}}} \right) \times {}^{{18}}{\text{F}}\;{\text{SUV}}$$

SUV (standardized uptake value) is defined as (18F/ml tissue) × (g body weight/total injected 18F). However, this formula was determined to fit the 18F signal to 10B concentrations in the rat model, and cannot be applied to other species.

Watanabe et al. compared biodistributions of the same doses (500 mg/kg) of 10B-BPA and 19F-FBPA given separately in two groups of SCC-VII-bearing mice according to two administration protocols: subcutaneous injection and continuous subcutaneous infusion [61]. No difference between 10B-BPA and 19F-FBPA was noted in the time course of 10B measured by ICP–AES in tumor or normal tissues with the same administration protocol. However, the continuous-infusion group showed lower normal tissue-to-blood ratios of 10B than the subcutaneous injection group, whereas the ratios of tumor to brain, tongue, and muscle were larger in the continuous-infusion group than in the subcutaneous injection group.

The 10B concentration in the blood, rather than in normal tissue such as muscle, is often used as the reference to calculate the 10B concentration in tumors for BNCT [62]. Lin et al. found that the tumor-to-blood and tumor-to-muscle ratios of 10B (measured ex vivo by ICP–AES) were variable at the time of measurement, but the muscle-to-blood ratio of 10B remained constant about 1.31 at 30–45 min after intravenous injection of 10B-BPA (400 mg/kg) into mice bearing SAS human oral carcinoma xenografts [40]. They suggested that 10B concentrations in tumor and normal tissues be estimated using the normal tissue-to-blood ratio as a conversion factor (1.31 in this animal case). They recommended that before BNCT of patients the T/N, the tumor-to-blood, and normal tissue-to-blood ratios be determined using 18F-FBPA PET.

Grunewald et al. also indicated the equivalent tissue distribution patterns of different administration doses of 18F-FBPA (1.5 mg/kg) and 10B-BPA (200 mg/kg) in tumor-bearing mice [58]. The 10B concentration was analyzed ex vivo by prompt gamma activation analysis or quantitative neutron capture radiography. The organ-to-plasma ratios of 10B were well correlated with the organ-to-plasma ratios of 18F-activity measured ex vivo using γ-counter (y = 0.83x + 0.75; r = 0.93, p < 0.0001), and also well-correlated with the organ-to-heart ratios of 18F-activity measured in vivo by last PET frame (y = 0.76x + 0.28; r = 0.83, p = 0.0001). Because it is assumed that the heart 18F-activity represents mainly blood 18F-activity, the organ-to-plasma ratios of 10B could be estimated by the organ-to-heart (blood pool in left ventricle) ratios of 18F-activity measured in vivo PET.

Yoshimoto et al. compared the pharmacokinetics of 18F-FBPA (0.6–3.1 mg/kg, estimated by the author) by bolus intravenous injection and continuous intravenous 30-min infusion with/without 10B-BPA (250 mg/kg) using a mouse model bearing six human tumor xenografts [63]. All six tumors showed increasing uptake of 18F-FBPA after a bolus injection. SUVs in LN-229 human glioma at 50–60 min after three administration methods were similar: bolus injection 1.26, continuous infusion without 10B-BPA 1.22, and continuous infusion with 10B-BPA 1.12. In six tumors, a significant association was revealed between tumor uptake of 18F-FBPA by bolus injection and by continuous infusion (r = 0.92, p < 0.01). 10B-Boron concentration measured ex vivo by ICP–AES in tumors correlated with 18F-FBPA uptake regardless of the administration method.

Enhancement of 18F-FBPA accumulation

For successful BPA BNCT high accumulation of 10B-BPA in tumors is essential. It has been reported that preloading with L-type amino acids such as l-tyrosine and l-DOPA enhances accumulation of l-BPA in malignant glioma and melanoma cells [48, 64, 65, 66]. When this approach was expanded to FBPA, similar enhancement phenomena were confirmed in the racemic 10B-enriched 19F-FBPA uptake in vitro in C6 glioma cells and in vivo in rats bearing C6 glioma by preloading of l-DOPA [67]. Additionally, 18F-FBPA uptake was enhanced in human and mouse tumor cell lines in vitro by preloading of l-DOPA, l-tyrosine, and l-BPA itself [37]. On the other hand, Grunewald et al. found that preloading of l-tyrosine, l-DOPA, and l-BPA did not increase the uptake of 18F-FBPA or 10B-BPA in any organs of mice bearing HuH-7 human hepatocellular carcinoma xenografts [58].

Regarding brain tumors, BBB disruption may be another approach to enhance the delivery of 10B-BPA [68, 69, 70]. In F98 glioma-bearing rats that received mannitol or cereport (a receptor-mediated permeabilizer-7), the tumor 10B concentrations after intracarotid injection of 10B-BPA were enhanced compared with controls, which resulted in significantly longer survival times after 10B-BPA BNCT. Using this animal model and a mannitol-induced hyperosmotic BBB disruption technique, Hsieh et al. confirmed enhanced tumor uptake and tumor-to-ipsilateral brain ratios of both 10B-BPA and 18F-FBPA after intracarotid injection [71]. They suggested that the pharmacokinetic parameter k12/k21 ratio (k12: rate constant of the central compartment to the peripheral compartment; k21: rate constant of the peripheral compartment to the central compartment) measured by 18F-FBPA PET may serve as a good indication for evaluating tumor uptake and tumor-to-brain ratio after intracarotid injection of 10B-BPA.

It is also known that pulsed high-intensity focused ultrasound (pulsed-HIFU) is able to disrupt the BBB to improve the delivery of macromolecules, such as antibodies and liposomal drugs. Wu et al. demonstrated that this technique enhanced tumor uptake of 18F-FBPA in mice bearing orthotopic SASC03 human tongue squamous carcinoma xenografts [49]. Immediately after pulsed-HIFU, tumor uptake of 18F-FBPA was 1.8 times that of the control at 60 min post injection; however, pulsed-HIFU did not affect the distribution of 18F-FBPA in most normal organs except the brain (3.1 times increase). The histology and expression of CD31 and Ki-67 were not changed by pulsed-HIFU. Yang et al. evaluated quantitatively the kinetics of 18F-FBPA in F98 glioma-bearing rats with pulsed-HIFU-induced BBB disruption [72], and found that the accumulation of 18F-FBPA in brain tumors and the tumor-to-contralateral brain ratio were significantly elevated. The K1/k2 ratio may be useful for indicating the degree of BBB disruption: K1 and k2 representing forward transport and reverse transport of 18F-FBPA across BBB.

Clinical studies

Radiation dosimetry

Before starting clinical studies on 18F-FBPA, radiation dosimetry was investigated in mice using racemic 18F-FBPA in a preclinical study [8]. Later, Ishiwata and co-workers evaluated the radiation dosimetry of l-enantiomer of 18F-FBPA in adult humans by dynamic whole-body PET scanning, and indicated that the effective dose of 18F-FBPA (23.9 µSv/MBq, n = 6) in humans was similar to that of other 18F-fluorinated PET probes such as 18F-FDG, O-(2-18F-fluoroethyl)-l-tyrosine, and 6-18F-fluoro-l-dopa (19–29, 16.5, 19.9 µSv/MBq, respectively) [73]. Kono et al. also reported slightly smaller effective doses of 18F-FBPA compared with 18F-FDG in adult and pediatric patients [74]. The effective dose of 18F-FBPA in pediatric patients (31 µSv/MBq, n = 3) was larger than that in adult patients (15 µSv/MBq, n = 6).

Assessment of 10B with 18F-FBPA-PET for l-BPA BNCT

Imahori, Mishima, and collaborators performed initial clinical trials of 18F-FBPA PET in patients with malignant brain tumors [13, 14, 15] and metastatic melanomas [16]. They performed dynamic PET scans with arterial blood sampling after intravenous injection of 18F-FBPA. First, Imahori et al. calculated the utilization ratio (integration of the 18F-activity that appears in arterial blood relative to the total injection dose) and incorporation constant (the amount of incorporated 18F-FBPA in the tumor tissue divided by plasma 18F-FBPA integrated over time) of 18F-FBPA, and estimated 10B-boron concentrations. The values estimated were generally higher but were very close to those measured ex vivo in surgical specimens of patients after 10B-BPA infusion by the ICP–AES [15]. To improve the 10B estimation method, Imahori et al. determined kinetic parameters (K1, k2, k3, and k4) based on a three-compartment model (Fig. 3a) [17, 18]. K1, which is mainly mediated by LAT-1 as described above, was a major factor determining the accumulation of 18F-FBPA, but k3 did not correlate with the degree of malignancy [17]. Subsequently, in seven patients with continuous infusion of 10B-BPA in a way similar to that used in the clinical practice of BNCT, they estimated 10B concentrations in tumors by the segmental convolution method using these rate constants, compared with those in the surgical specimens, and verified the 18F-FBPA PET method to estimate 10B concentrations [18]. Similarly, Kabalka et al. further extended this model to a four-compartment model for 18F-FBPA PET, and determined the optimal irradiation window for effective 10B-BPA BNCT from the calculated tissue 18F-activity based on a simulated continuous infusion of 18F-FBPA using kinetic parameters [19].

Fig. 3

Kinetic models of 18F-FBPA. a Reversible two-tissue compartmental model. The model proposed by Imahori et al. was simplified [17]. b One-tissue compartmental model. The model has a very low or negligible non-diffusible component (retention process). c Irreversible two-tissue compartmental model. The possible model for melanoma based on the incorporation of 18F-FBPA into melanogenesis [10, 11]

It is notable that the compartment analyses by Imahori et al. and Kabalka et al. included the retention process of 18F-FBPA or non-diffusible 18F-FBPA (expressed as k3 and k4) in malignant brain tumors in spite of the metabolic stability of 18F-FBPA because of the increasing time–activity curves for about 40 min followed by a very slow decrease. On the other hand, Havu-Aurén et al. reported that benign neoplasms showed an initial uptake of 18F-FBPA at 3–5 min post injection followed by a gradual decrease, indicating very low or negligible retention processes (corresponding to the model in Fig. 3b), and that K1 was higher than k3, suggesting that transport rather than metabolism governed the uptake of 18F-FBPA [35]. They described that some of these benign neoplasms might be amenable to BNCT based on the results of 18F-FBPA PET. In our experience, many tumors in the head and neck showed similar time–activity curves without the retention processes, like in benign neoplasms. Only in malignant melanomas, free 18F-FBPA may be incorporated into melanin by non-enzymatic polymerization in melanogenesis (Fig. 3c), as suggested in metabolite analysis of 18F-FBPA in melanoma-bearing animal models [10, 11]. In a kinetic analysis of O-2-18F-fluoroethyl-l-tyrosine with characteristics similar to those of 18F-FBPA [75, 76, 77], it was best modeled by a reversible two-tissue compartmental model rather than a one-tissue compartmental model or irreversible two-tissue compartment model [77].

These dynamic 18F-FBPA PET studies were a practical and clinically useful method as a prognostic and therapeutic indicator of malignant brain tumors [78], and were applied to planning BNCT for malignant brain tumors [79] and malignant melanoma [80]. In 22 of 98 glioma patients in Finland who received BNCT, from 1999 to 2011, a kinetic model based on 18F-FBPA PET predicted + 11% and + 36% higher total weighted doses delivered to tumor and normal brain, respectively, than previously estimated doses due to the non-constant tumor-to-blood concentration ratios [81].

Practical use of [18F]FBPA PET for BNCT

18F-FBPA PET before BNCT is useful for patient selection and prediction of the distribution and accumulation of 10B-BPA, and follow-up 18F-FBPA PET after BNCT is helpful to evaluate therapeutic effect. For effective BNCT accumulation of a large amount of 10B atoms, approximately 109 atoms of 10B per cell or 20–35 µg 10B/g, in tumor cells are required, and at the same time a high T/N10B concentration ratio of greater than 1 and preferably 3–5 is required to ensure a therapeutic dose to the tumor with a minimal background radiation dose [82, 83]. From a practical point of view, there is an easy approach for 18F-FBPA PET for screening of patients suitable for BNCT. To evaluate the T/N ratio of the 10B concentration being over 3.0 pre-BNCT, it may be sufficient to compare the T/N ratio of 18F-FBPA uptake obtained by an appropriate static scan of 18F-FBPA PET. Nariai et al. indicated that in patients with malignant brain tumors the T/B ratio of 18F-FBPA after a bolus injection of 18F-FBPA had a significant linear correlation with the T/B ratio of 10B estimated by 1-h constant infusion of 10B-BPA, as simulated using the Runge–Kutta algorithm [84]. This type of quantitative evaluation has not been tried in other malignant tumors; however, Morita et al. recently reported that the T/N ratios of 18F-FBPA in head and neck cancers and malignant melanoma were not significantly changed over 120 min in spite of a slight decrease in 18F-FBPA uptake [85]. In evaluating the T/N ratio of 18F-FBPA in patients with head and neck cancers, it is notable that the uptake of 18F-FBPA was higher in the dorsum tongue, submandibular gland, parotid gland, and tongue in this order among normal tissues in the oral and maxillofacial regions than in normal brain [86]. The averaged ratios (n = 8) of T/B and tumor-to-dorsum tongue were 3.25 (range 2.34–5.40) and 1.25 (range 0.95–2.10), respectively. The ratios varied depending on the location of the tumor, type of tumor, and scan time post injection. For example, in Fig. 4a, tumor (salivary gland duct carcinoma)-to-surrounding normal tissue ratios was 3.2, whereas the tumor-to-contralateral normal salivary gland ratio was 2.3 (unpublished data). In an early study, Kabalka et al. indicated that the lung and peri-oral mucous gland showed intense 18F-FBPA activity [80].

Fig. 4

18F-FBPA, 11C-methionine, and 18F-FDG PET/CT images of patients with salivary gland duct carcinoma (upper row) and squamous cell carcinoma (lower row). Three PET scans were performed during a 2-week interval in the Southern TOHOKU Research Institute for Neuroscience (unpublished data, approved by the institutional ethics committee #224). The PET/CT scanner used was Discovery PET/CT 610 (GE Healthcare, Milwaukee, WI), and the injected radioactivity doses of 18F-FBPA, 11C-methionine, and 18F-FDG (upper low and lower row) were 4.3 and 4.6, 6.7 and 7.4, and 3.6 and 3.6 MBq/kg body weight, respectively. Yellow arrows; carcinomas; white arrows, salivary gland (upper row) and cerebellum (lower row). PET images are shown in the scale of SUV 0–6 except for 18F-FDG in the lower row (SUV 0–10). SUVmax values of 18F-FBPA (40–60 min post injection), 11C-methionine (20–30 min post injection), and 18F-FDG (50–60 min post injection) were 3.6, 9.7, and 7.1, respectively, in the upper row, and 5.9, 7.2, and 18.5, respectively, in the lower row

To predict the accumulation (concentration) of 10B-BPA in tumors, first dynamic and quantitative 18F-FBPA PET was performed as described above. On the contrary, in BNCT the 10B concentration in the blood is often used as the reference to calculate the 10B concentration in tumors [62]. Therefore, in the practical use of 18F-FBPA PET for 10B-BPA BNCT, the 10B concentration in the tumor has been estimated by multiplying the 10B concentration in blood measured during neutron irradiation by the tumor-to-blood ratio of 18F-FBPA PET [87]. For this purpose, Isohashi et al. proposed the use of the image-derived tumor-to-blood ratio of 18F-FBPA [59]. They used 18F-activity in the left ventricle instead of 18F-activity in the blood, with correction for underestimation due to the partial volume effect and reduction of 18F-activity in the blood.

Estimating the 10B concentration by relative tumor uptake of 18F-FBPA against normal tissue and plasma has a certain practical benefit but does not predict possible adverse effects on the surrounding normal tissue by neutron irradiation. To avoid these risks the 10B concentration of the normal tissue should be estimated correctly. Recently, Shimosegawa et al. proposed a method to evaluate 10B-BPA accumulation directly in normal organs by 18F-FBPA PET before BNCT [88]. They assumed boldly that 10B-BPA and 18F-FBPA behave in the body as the same compound even after different injection doses, and they calculated the 10B concentrations in organs by multiplying the relative accumulation of 18F-FBPA per g tissue by the therapeutic dose (g) of l-BPA. At present, this method has not been validated in BNCT.

Thus far, 18F-FBPA PET has been utilized in 10B-BPA BNCT for patients with malignant brain tumors, recurrent tumors of the head and neck region, and malignant melanomas by many investigators (see reviews, [1, 2, 21, 22, 23, 89]). 18F-FBPA PET was a part of the inclusion criteria for BNCT clinical phase I/II trials of the treatment of recurrent head and neck cancers in Finland [90] and in Taiwan [91, 92]. In the Finnish study, 18F-FBPA PET was performed in 15 of 30 patients before BNCT and then in 7 patients after BNCT to evaluate treatment response. In the Taiwanese study, in 17 patients the T/N ratio of 18F-FBPA was > 2.5 as an inclusion criterion for one- or two-fractions of BNCT, and the treatment response was evaluated again by 18F-FBPA PET.

As shown in the Finnish study, 18F-FBPA PET post BNCT is involved to evaluate the treatment response in the typical BNCT protocol. For this purpose, 11C-methionine PET was equally useful as 18F-FBPA PET [93, 94]. 18F-FDG PET, which is generally used to evaluate the efficacy of treatment of tumors, was also used successfully to evaluate maxillary sinus cancer invading into the orbital fossa after BNCT [95]; however, it should be noted that 18F-FDG accumulates in the inflammatory tissue post radiotherapy and normal brain.

Applicability of other PET probes for BNCT

If PET diagnosis with more common probes such as 18F-FDG and 11C/18F-amino acids is applicable to the screening of patients to assess their suitability for BNCT, BNCT can be performed effectively. Nariai et al. performed PET with 18F-FBPA and 11C-methionine in 12 patients with malignant glioma on the same day, and found that the estimated T/B ratio of 10B after a 1-h constant infusion of 10B-BPA and T/B ratios of 18F-FBPA and 11C-methionine on static conditions showed significant linear correlations [84]. Yamamoto et al. used both 18F-FBPA and 11C-methionine to evaluate 10B-BPA uptake in a BNCT trial of glioblastoma [96]. Watanabe et al. also compared 18F-FBPA and 11C-methionine PET in seven patients with head and neck tumors with intervals of less than 3 weeks in six cases except for a 123-day interval in one case [97]. They also described that 11C-methionine PET might be used instead of 18F-FBPA PET to select candidates for BNCT. However, 11C-methionine was taken up at higher levels than 18F-FBPA by tumors, as well as many normal tissues as a natural amino acid, and therefore, the T/N ratios would not be suitable for evaluating tumor accumulation in some normal organs such as the submandibular gland, liver, heart, stomach, pancreas, spleen, and bone marrow.

Kurihara et al. also compared 18F-FBPA and 18F-FDG PET in 20 patients with head and neck cancers [98, 99]. A significant correlation was observed between maximal SUVs (SUVmax) of 18F-FBPA (4.13, n = 20) and 18F-FDG (9.40, n = 20), and an SUVmax of 18F-FDG ≥ 5.0 is considered to correspond to a T/N ratio of 18F-FBPA ≥ 2.5 as the threshold value for prediction of BNCT [98].

Figure 4 shows representative images of 18F-FBPA, 11C-methionine, and 18F-FDG PET (unpublished data). The characteristics of the three probes are clearly demonstrated: a lower tumor uptake of 18F-FBPA compared with 11C-methionine and 18F-FDG and a high uptake of 11C-methionine in the normal salivary glands.

General use of 18F-FBPA in PET diagnosis

In general, 11C/18F-amino acids such as 11C-methionine and O-2-18F-fluoroethyl-l-tyrosine are useful for the diagnosis of brain tumors, and 18F-FBPA is also useful, as described above. A benefit of artificial amino acids such as O-2-18F-fluoroethyl-l-tyrosine and 18F-FBPA is their very low uptake in the normal brain due to rapid clearance without metabolic alteration, although 11C-methionine accumulates in the normal brain to a certain degree due to the metabolic pathways of methionine. Consequently, it is considered that artificial amino acids give higher contrast tumor images than 11C-methionine. This is true when the T/B ratio of 18F-FBPA was compared to that of 11C-methionine in 12 patients with glioma on the same day [84]. The ratio of 18F-FBPA was 1.61-fold higher than that of 11C-methionine, although the SUV of 18F-FBPA was 0.87-fold lower than that of 11C-methionine (personal communication).

Miyatake and colleagues reported that 18F-FBPA PET is useful for differential diagnosis among radiation necrosis, pseudo-progression, and progression after BNCT for malignant brain tumors [100, 101, 102, 103]. They further described that both 18F-FBPA and 11C-methionine PET are equally useful for this purpose [94]. Prior to these studies, the usefulness of 11C-methionine PET for the differentiation of recurrent and radiation necrosis after stereotactic radiosurgery of malignant glioma was reported [104]. Recently Beshr et al. confirmed the possibility of 18F-FBPA PET for the differentiation of recurrence from radiation necrosis in 12 patients with irradiated brain tumors. The four parameters investigated were mean SUV, SUVmax, metabolic tumor volume, and total lesion uptake, and their ratios of recurrence to radiation necrosis were 2.5, 4.2, 3.8, and 9.8, respectively [105].

Differential diagnosis between inflammatory lesions and tumors by 18F-FBPA PET was suggested from an animal study [42]; however, no clinical studies have been reported to date.

As described in section “Tumor accumulation of 18F-FBPA and PET imaging”, melanomas in animal models showed higher uptake of 18F-FBPA than non-melanoma tumors, probably due to the trapping mechanism of 18F-FBPA in melanogenesis. This melanoma-preferential uptake of 18F-FBPA was confirmed clinically by Morita et al. [85]. 18F-FBPA showed a slight washout pattern in squamous cell carcinoma of the head and neck (n = 20) and a persistent pattern in malignant melanoma (n = 8). The melanomas-to-squamous cell carcinoma uptake ratios of 18F-FBPA increased slightly (1.69, 1.73, and 1.93) with time post-injection (30, 60, and 120 min, respectively).

Concluding remarks

18F-FBPA has been developed for monitoring the pharmacokinetics of 10B-BPA used in BNCT and characterized as a 10B-BPA probe in basic studies in vitro and in vivo of tumor imaging potential, transport, cellular distribution, metabolism, validity, and reliability. Tumor uptake of 18F-FBPA depends mainly on transport by LAT. Tumoral distribution of 18F-FBPA was primarily related to the activities of DNA synthesis and melanogenesis. Pharmacokinetics of 18F-FBPA reflects mostly that of BPA, although there are slight discrepancies between the two compounds. Clinically, kinetic analysis based on 18F-FBPA PET has successfully estimated the 10B-concentration in tumor tissues, and the significance of 18F-FBPA PET in 10B-BPA BNCT has been established. 18F-FBPA PET has been involved in the practical 10B-BPA BNCT for the treatment of patients with intractable tumors and used for screening of patients, prediction of the distribution and accumulation of 10B-BPA, and the evaluation of treatment. Static 18F-FBPA PET scans are generally used to measure the T/N and tumor-to-blood ratios of 18F-FBPA. However, it has not necessarily been clarified whether PET findings predict the prognosis of BNCT. Furthermore, recent studies have suggested that 18F-FBPA PET could be used more elaborately for successful 10B-BPA BNCT. Apart from BNCT, 18F-FBPA is considered to be a useful PET probe for tumor diagnosis; however, for general diagnosis in nuclear medicine, the third-generation synthesis of 18F-FBPA by nucleophilic fluorination using 18F-fluoride that will enable higher activity amounts and higher molar activities, is required.

Notes

Acknowledgements

The author thanks Dr. Kazuo Kubota and Dr. Katsumi Hirose at the Southern TOHOKU Research Institute of Neuroscience for valuable discussions. The author would like to thank the Japanese Society of Neutron Capture Therapy for granting the author the Mishima Memorial Chemistry Award in August 2016.

Funding

Funding was provided by Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research (B) no. 16H05396).

Compliance with ethical standards

Conflict of interest

Department of Biofunctional Imaging (Kiichi Ishiwata) at Fukushima Medical University is endowed by Southern TOHOKU Research Institute for Neuroscience.

References

  1. 1.
    Wittig A, Michel J, Moss RL, Stecher-Rasmussen F, Arlinghaus HF, Bendel P, et al. Boron analysis and boron imaging in biological materials for boron neutron capture therapy (BNCT). Crit Rev Oncol Hematol. 2008;68:66–90.  https://doi.org/10.1016/j.critrevonc.2008.03.004.CrossRefPubMedGoogle Scholar
  2. 2.
    Barth RF, Vicente MGH, Harling OK, Kiger WS III, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7:146.  https://doi.org/10.1186/1748-717X-7-146.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Moss RL. Critical review, with an optimistic outlook, on boron neutron capture therapy (BNCT). Appl Radiat Isot. 2014;88:2–11.  https://doi.org/10.1016/j.apradiso.2013.11.109.CrossRefPubMedGoogle Scholar
  4. 4.
    Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun. 2018;38:35.  https://doi.org/10.1186/s40880-018-0299-7.CrossRefGoogle Scholar
  5. 5.
    Synder HR, Reedy AJ, Lennarz WMJ. Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine. J Am Soc Chem. 1958;80:835–8.  https://doi.org/10.1021/ja01537a021.CrossRefGoogle Scholar
  6. 6.
    Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res. 1990;50:138–41.PubMedGoogle Scholar
  8. 8.
    Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: a target compound for PET and boron neutron capture therapy. Appl Radiat Isot. 1991;42:325–8.  https://doi.org/10.1016/0883-2889(91)90133-L.CrossRefGoogle Scholar
  9. 9.
    Ishiwata K, Ido T, Kawamura M, Kubota K, Ichihashi M, Mishima Y. 4-Borono-2-[18F]fluoro-d,l-phenylalanine as a target compound for boron neutron capture therapy: tumor imaging potential with positron emission tomography. Nucl Med Biol. 1991;18:745–51.  https://doi.org/10.1016/0883-2897(91)90013-B.CrossRefGoogle Scholar
  10. 10.
    Ishiwata K, Ido T, Honda C, Kawamura M, Ichihashi M, Mishima Y. 4-Borono-2-[18F]fluoro-d,l-phenylalanine: a possible tracer for melanoma diagnosis with PET. Nucl Med Biol. 1992;19:311–8.  https://doi.org/10.1016/0883-2897(92)90116-G.CrossRefGoogle Scholar
  11. 11.
    Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, et al. A unique in vivo assessment of 4-[10B]borono-l-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanoma using positron emission tomography and 4-borono-2-[18F]fluoro-l-phenylalanine. Melanoma Res. 1992;2:171–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kubota R, Yamada S, Ishiwata K, Tada M, Ido T, Kubota K. Cellular accumulation of 18F-labelled boronophenylalanine depending on DNA synthesis and melanin incorporation: a double-tracer microautoradiographic study of B16 melanomas in vivo. Br J Cancer. 1993;67:701–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Imahori Y, Ueda S, Ohmori Y, Yoshino E, Ono K, Kobayashi T, et al. A basic concept for PET-BNCT system. In: Mishima Y, editor. Cancer neutron capture therapy. New York: Plenum Press; 1996. pp. 691–6.CrossRefGoogle Scholar
  14. 14.
    Ueda S, Imahori Y, Ohmori Y, Yoshino E, Ono K, Kobayashi T, et al. Positron emission tomography and boron neutron capture therapy system to the patient with malignant brain tumor: the first clinical trial using 10B-BPA. In: Mishima Y, editor. Cancer neutron capture therapy. New York: Plenum Press; 1996. pp. 823–7.CrossRefGoogle Scholar
  15. 15.
    Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res. 1998;4:1825–32.PubMedGoogle Scholar
  16. 16.
    Mishima Y, Imahori Y, Honda C, Hiratsuka J, Ueda S, Ido T. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol. 1997;33:163–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998;39:325–3.PubMedGoogle Scholar
  18. 18.
    Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833–41.PubMedGoogle Scholar
  19. 19.
    Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CPD, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med. 1997;38:1762–7.PubMedGoogle Scholar
  20. 20.
    Menichetti L, Cionini L, Sauerwein WA, Altieri S, Solin O, Minn H, et al. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT. Appl Radiat Isot. 2009;67:351–4.  https://doi.org/10.1016/j.apradiso.2009.03.062 CrossRefGoogle Scholar
  21. 21.
    Nariai T, Ishiwata K. Analysis and imaging: PET. In: Sauerwein WAG, Wittig A, Moss R, Nakagawa Y, editors. Neutron capture therapy, principles and applications. Berlin: Springer; 2012. pp. 201–12.  https://doi.org/10.1007/978-3-642-31334-9_11.CrossRefGoogle Scholar
  22. 22.
    Evangelista L, Jori G, Martini D, Sotti G. Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: a critical and clinical overview of the literature. Appl Radiat Isot. 2013;74:91–101.  https://doi.org/10.1016/j.apradiso.2013.01.001.CrossRefPubMedGoogle Scholar
  23. 23.
    Miyatake S, Kawabata S, Hiramatsu R, Kuroiwa T, Suzuki M, Kondo N, et al. Boron neutron capture therapy for malignant brain tumors. Neurol Med Chir (Tokyo). 2016;56:361–71.  https://doi.org/10.2176/nmc.ra.2015-0297.CrossRefGoogle Scholar
  24. 24.
    Blue T, Yanch J. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors. J Neurooncol. 2003;62:19–31.PubMedGoogle Scholar
  25. 25.
    Kreiner AJ, Bergueiro J, Cartelli D, Baldo M, Castell W, Asoia JG, Padulo J, Suárez Sandín JC, Igarzabal M, Erhardt J, Mercuri D, Valda AA, Minsky DM, Debray ME, Somacal HR, Capoulat ME, Herrera MS, Del Grosso MF, Gagetti L, Anzorena MS, Canepa N, Real N, Gun M, Tacca H. Present status of accelerator-based BNCT. Rep Pract Oncol Radiother. 2016;21:95–101.  https://doi.org/10.1016/j.rpor.2014.11.004.CrossRefPubMedGoogle Scholar
  26. 26.
    Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Kinashi Y, Kashino G, et al. Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy. Nucl Instrum Methods Phys Res B. 2009;267:1970–7.  https://doi.org/10.1016/j.nimb.2009.03.095.CrossRefGoogle Scholar
  27. 27.
    Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Mitsumoto T, Fujita K, et al. Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl Radiat Isot. 2011;69:1642–5.  https://doi.org/10.1016/j.apradiso.2011.03.020.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang HE, Liao AH, Deng WP, Chang PF, Chen JC, Chen FD, et al. Evaluation of 4-borono-2-18F-fluoro-l-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma bearing rat model. J Nucl Med. 2004;45:302–8.PubMedGoogle Scholar
  29. 29.
    Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.  https://doi.org/10.1186/s13550-014-0070-2.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ishiwata K, Ebinuma R, Watanabe C, Hayashi K, Toyohara J. Reliable radiosynthesis of 4-[10B]borono-2-[18F]fluoro-l-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis. Ann Nucl Med. 2018;32:463–73.  https://doi.org/10.1007/s12149-018-1268-6.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Nickles RJ, Daube ME, Ruth TJ. An 18O2 target for the production of [18F]F2. Int J Appl Radiat Isot. 1984;35:117–22.CrossRefGoogle Scholar
  32. 32.
    Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol. 1997;24:677–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Mairinger S, Stanek J, Wanek T, Langer O, Kuntner C. Automated electrophilic radiosynthesis of [18F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. Appl Radiat Isot. 2015;104:124–7.  https://doi.org/10.1016/j.apradiso.2015.06.034.CrossRefPubMedGoogle Scholar
  34. 34.
    Vähätalo JK, Eskola O, Bergman J, Forsback S, Lehikoinen P, Jääskeläinen J, et al. Synthesis of 4-dihydroxyboryl-2-[18F]fluorophenylalanine with relatively high-specific activity. J Label Compd Radiopharm. 2002;45:697–704.  https://doi.org/10.1002/jlcr.600.CrossRefGoogle Scholar
  35. 35.
    Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, et al. Uptake of 4-borono-2-[18F]fluoro-l-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. Eur J Nucl Med Mol Imaging. 2007;34:87–94.  https://doi.org/10.1007/s00259-006-0154-y.CrossRefPubMedGoogle Scholar
  36. 36.
    Hamacher K. Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added [18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.PubMedGoogle Scholar
  37. 37.
    Wingelhofer B, Kreis K, Mairinger S, Muchitsch V, Stanek J, Wanek T, et al. Preloading with l-BPA, l-tyrosine and l-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. Appl Radiat Isot. 2016;118:67–72.  https://doi.org/10.1016/j.apradiso.2016.08.026.CrossRefPubMedGoogle Scholar
  38. 38.
    Coderre JA, Glass JD, Fairchild RG, Roy U, Cohen S, Fand I. Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy. Cancer Res. 1987;47,:6377–83.Google Scholar
  39. 39.
    Kanazawa M, Nishiyama S, Hashimoto F, Kakiuchi T, Tsukada H. Evaluation of d-isomers of 4-borono-2-18F-fluoro-phenylalanine and O-11C-methyltyrosine as brain tumor imaging agents: a comparative PET study with their l-isomers in rat brain glioma. EJNMMI Res. 2018;8:47.  https://doi.org/10.1186/s13550-018-0404-6.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lin YC, Hwang JJ, Wang SJ, Yang BH, Chang CW, Hsiao MC, et al. Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model. Anticaner Res. 2012;32:2657–64.Google Scholar
  41. 41.
    Chen JC, Chang SM, Hsu FY, Wang HE, Liu RS. MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma. Appl Radiat Isot. 2004;61:887–91.  https://doi.org/10.1016/j.apradiso.2004.05.056.CrossRefPubMedGoogle Scholar
  42. 42.
    Watabe T, Ikeda H, Nagamori S, Wiriyasermkul P, Tanaka Y, Naka S, et al. 18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2017;44:321–31.  https://doi.org/10.1007/s00259-016-3487-1.CrossRefPubMedGoogle Scholar
  43. 43.
    Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-18F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 2013;40:625–9.  https://doi.org/10.1016/j.nucmedbio.2013.02.010.CrossRefPubMedGoogle Scholar
  44. 44.
    Porcari P, Capuani S, D’Amore E, Lecce M, La Bella A, Fasano F, et al. In vivo 19F MRI and 19F MRS of 19F-labelled boronophenylalanine-fructose complex on a C6 rat glioma model to optimize boron neutron capture therapy (BNCT). Phys Med Biol. 2008;53:6979–89.  https://doi.org/10.1088/0031-9155/53/23/021.CrossRefPubMedGoogle Scholar
  45. 45.
    Geninatti-Crich S, Deagostino A, Toppino A, Alberti D, Venturello P, Aime S. Boronated compounds for imaging guided BNCT applications. Anticancer Agents Med Chem. 2012;12:543–53.CrossRefPubMedGoogle Scholar
  46. 46.
    Bradshaw KM, Schweizer MP, Glover GH, Hadley JR, Tippets R, Tang PP, et al. BSH distributions in the canine head and a human patient using 11B MRI. Mag Reson Med. 1995;34:48–56.CrossRefGoogle Scholar
  47. 47.
    Kabalka GW, Tang C, Bendel P. The role of boron MRI in boron neutron capture therapy. J Neurooncol. 1997;33:153–61.CrossRefPubMedGoogle Scholar
  48. 48.
    Bendel P, Koudinova N, Salomon Y. In vivo imaging of the neutron capture therapy agent BSH in mice using 10B MRI. Magn Reson Med. 2001;46:13–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Wu CY, Chan PC, Chou LS, Chang CW, Yang FY, Liu RS, et al. Pulsed-focused ultrasound enhances boron drug accumulation in a human head and neck cancer xenograft-bearing mouse model. Mol Imaging Biol. 2014;16:95–101.  https://doi.org/10.1007/s11307-013-0675-2.CrossRefPubMedGoogle Scholar
  50. 50.
    Bailey SF, Kabalka GW, Fuhr JE. In vitro effects of boron-containing compounds upon glioblastoma cells. Proc Soc Exp Biol Med. 1997;216:452–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Chandra S, Kabalka GW, Lorey IIDR, Smith DR, Coderre JA. Imaging of fluorine and boron from fluorinated boronophenylalanine in the same cell at organelle resolution by correlative ion microscopy and confocal laser scanning microscopy. Clin Cancer Res. 2002;8:2675–83.PubMedGoogle Scholar
  52. 52.
    Wang HE, Wu SY, Chang CW, Liu RS, Hwang LC, Lee TW, et al. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model. Nucl Med Biol. 2005;32:367–75.  https://doi.org/10.1016/j.nucmedbio.2005.01.005.CrossRefPubMedGoogle Scholar
  53. 53.
    Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 2000;153(2):173–80.CrossRefPubMedGoogle Scholar
  54. 54.
    Detta A, Cruickshank GS. l-Amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–32.  https://doi.org/10.1158/0008-5472.CAN-08-2345.CrossRefPubMedGoogle Scholar
  55. 55.
    Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015;106:279–86.  https://doi.org/10.1111/cas.12602.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Coenen HH, Kling P, Stöcklin G. Cerebral metabolism of l-[2-18F]fluorotyrosine, a new PET tracer for protein synthesis. J Nucl Med. 1989;30:1367–72.PubMedGoogle Scholar
  57. 57.
    Bendel P, Wittig A, Basilico F, Mauri PL, Sauerwein W. Metabolism of borono-phenylalanine–fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients—results from EORTC trial 11001. J Pharm Biomed Anal. 2010;51:284–7.  https://doi.org/10.1016/j.jpba.2009.08.018.CrossRefPubMedGoogle Scholar
  58. 58.
    Grunewald C, Sauberer M, Filip T, Wanek T, Stanek J, Mairinger S, et al. On the applicability of [18F]FBPA to predict l-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. Nucl Med Biol. 2017;44:83–9.  https://doi.org/10.1016/j.nucmedbio.2016.08.012.CrossRefPubMedGoogle Scholar
  59. 59.
    Isohashi K, Shimosegawa E, Naka S, Kanai Y, Horitsugi G, Mochida I, et al. Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-18F-fluorophenylalanine (FBPA) PET study. EJNMMI Res. 2016;6:75.  https://doi.org/10.1186/s13550-016-0230-7.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Watabe T, Hanaoka K, Naka S, Kanai Y, Ikeda H, Aoki M, et al. Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET. Ann Nucl Med. 2017;31:481–5.  https://doi.org/10.1007/s12149-017-1172-5.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y, et al. Comparison of the pharmacokinetics between l-BPA and l-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [18F]-l-FBPA positron emission tomography in boron neutron capture therapy. BMC Cancer. 2016;16:859.  https://doi.org/10.1186/s12885-016-2913-x.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, et al. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys. 1998;40:829–34.CrossRefPubMedGoogle Scholar
  63. 63.
    Yoshimoto M, Honda N, Kurihara H, Hiroi K, Nakamura S, Ito M, et al. Non-invasive estimation of 10B-4-borono-l-phenylalanine derived boron concentration in tumors by PET using 4-borono-2-18F-fluoro-phenylalanine. Cancer Sci. 2018;109:1617–26.  https://doi.org/10.1111/cas.13553.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Papaspyrou M, Feinendegen EL, Muüller-Gärtner HW. Preloading with l-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res. 1994;54:6311–4.PubMedGoogle Scholar
  65. 65.
    Capuani S, Gili T, Bozzali M, Russo S, Porcari P, Cametti C, et al. l-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy. Int J Radiat Oncol Biol Phys. 2008;72:562–7.  https://doi.org/10.1016/j.ijrobp.2008.06.1493.CrossRefPubMedGoogle Scholar
  66. 66.
    Yang W, Barth RF, Huo T, Kabalka GW, Shaikh AL, Haider SA, et al. Effects of l-DOPA pre-loading on the uptake of boronophenylalanine using the F98 glioma and B16 melanoma models. Appl Radiat Isot. 2014;88:69–73.  https://doi.org/10.1016/j.apradiso.2014.01.002.CrossRefPubMedGoogle Scholar
  67. 67.
    Porcari P, Capuani S, D’Amore E, Lecce M, La Bella A, Fasano F, et al. In vivo 19F MR imaging and spectroscopy for the BNCT optimization. Appl Radiat Isot. 2009;67(7–8 Suppl):S365–8.  https://doi.org/10.1016/j.apradiso.2009.03.065.CrossRefPubMedGoogle Scholar
  68. 68.
    Barth RF, Yang W, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood–brain barrier disruption. Cancer Res. 1997;57:1129–36.PubMedGoogle Scholar
  69. 69.
    Barth RF, Yang W, Bartus RT, Moeschberger ML, Goodman JH. Enhanced delivery of boronophenylalanine for boron neutron capture therapy of brain tumors using the bradykinin analog cereport (receptor-mediated permeabilizer-7). Neurosurgery. 1999;44:351–36.CrossRefPubMedGoogle Scholar
  70. 70.
    Barth RF, Yang W, Bartus RT, Rotaru JH, Ferketich AK, Moeschberger ML, et al. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood–brain barrier opening to improve delivery of boronophenylalanine. Int J Radiat Oncol Biol Phys. 2002;52:858–68.CrossRefPubMedGoogle Scholar
  71. 71.
    Hsieh CH, Chen YF, Chen FD, Hwang JJ, Chen JC, Liu RS, et al. Evaluation of pharmacokinetics of 4-borono-2-18F-fluoro-l-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood–brain barrier disruption. J Nucl Med. 2005;46:1858–65.PubMedGoogle Scholar
  72. 72.
    Yang FY, Chang WY, Li JJ, Wang HE, Chen JC, Chang CW. Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood–brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy. J Nucl Med. 2014;55:616–21.  https://doi.org/10.2967/jnumed.113.125716.CrossRefPubMedGoogle Scholar
  73. 73.
    Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.  https://doi.org/10.1007/s12149-013-0685-9.CrossRefPubMedGoogle Scholar
  74. 74.
    Kono Y, Kurihara H, Kawamoto H, Yasui N, Honda N, Igaki H, et al. Radiation absorbed dose estimates for 18F-BPA PET. Acta Radiol. 2017;58:1094–101.  https://doi.org/10.1177/0284185116688378.CrossRefPubMedGoogle Scholar
  75. 75.
    Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42.  https://doi.org/10.1007/s00259-007-0534-y.CrossRefPubMedGoogle Scholar
  76. 76.
    Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014;16:434–40.  https://doi.org/10.1093/neuonc/not199.CrossRefPubMedGoogle Scholar
  77. 77.
    Koopman T, Verburg N, Schuit RC, Pouwels PJW, Wesseling P, Windhorst AD, et al. Quantification of O-(2-[18F]fluoroethyl)-l-tyrosine kinetics in glioma. EJNMMI Res. 2018;8:72.  https://doi.org/10.1186/s13550-018-0418-0.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Takahashi Y, Imahori Y, Mineura K. Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res. 2003;9:5888–95.PubMedGoogle Scholar
  79. 79.
    Nichols T, Kabalka GW, Miller LF, Khan MK, Smith GT. Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys. 2002;29:2351–8.  https://doi.org/10.1118/1.1507780.CrossRefPubMedGoogle Scholar
  80. 80.
    Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK, Busse PM. The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neurooncol. 2003;62:187–95.PubMedGoogle Scholar
  81. 81.
    Koivunoro H, Hippeläinen E, Auterinen I, Kankaanranta L, Kulvik M, Laakso J, et al. Biokinetic analysis of tissue boron (10B) concentrations of glioma patients treated with BNCT in Finland. Appl Radiat Isot. 2015;106:189–94.  https://doi.org/10.1016/j.apradiso.2015.08.014.CrossRefPubMedGoogle Scholar
  82. 82.
    Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, et al. The chemistry of neutron capture therapy. Chem Rev. 1998;98:1515–62.CrossRefPubMedGoogle Scholar
  83. 83.
    Barth RF, Soloway AH. Boron neutron capture therapy of brain tumors—current status and future prospects. J Neurooncol. 1997;33:3–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67(7–8 Suppl):348–50.  https://doi.org/10.1016/j.apradiso.2009.03.061.CrossRefGoogle Scholar
  85. 85.
    Morita T, Kurihara H, Hiroi K, Honda N, Igaki H, Hatazawa J, et al. Dynamic changes in 18F-borono-l-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection. Radiat Oncol. 2018;13:4.  https://doi.org/10.1186/s13014-017-0949-y.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Ariyoshi Y, Shimahara M, Kimura Y, Ito Y, Shimahara T, Miyatake S, et al. Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions. Oncol Lett. 2011;2:423–7.  https://doi.org/10.3892/ol.2011.265.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146–53.  https://doi.org/10.1093/jrr/rrt098.CrossRefPubMedGoogle Scholar
  88. 88.
    Shimosegawa E, Isohashi K, Naka S, Horitsugi G, Hatazawa J. Assessment of 10B concentration in boron neutron capture therapy: potential of image-guided therapy using 18FBPA PET. Ann Nucl Med. 2016;30:749–55.  https://doi.org/10.1007/s12149-016-1121-8.CrossRefPubMedGoogle Scholar
  89. 89.
    Nedunchezhian K, Aswath N, Thiruppathy M, Thirugnanamurthy S. Boron neutron capture therapy—a literature review. J Clin Diagn Res. 2016;10:ZE01–4.  https://doi.org/10.7860/JCDR/2016/19890.9024.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012;82:e67–75.  https://doi.org/10.1016/j.ijrobp.2010.09.057.CrossRefPubMedGoogle Scholar
  91. 91.
    Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YWH, et al. BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot. 2011;69:1803–6.  https://doi.org/10.1016/j.apradiso.2011.03.008.CrossRefPubMedGoogle Scholar
  92. 92.
    Wang LW, Liu YWH, Chou FI, Jiang D-H. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing–Hua open pool reactor. Cancer Commun. 2018;38:37.  https://doi.org/10.1186/s40880-018-0295-y.CrossRefGoogle Scholar
  93. 93.
    Aiyama H, Nakai K, Yamamoto T, Nariai T, Kumada H, Ishikawa E, et al. A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba. Appl Radiat Isot. 2011;69:1819–22.  https://doi.org/10.1016/j.apradiso.2011.04.031.CrossRefPubMedGoogle Scholar
  94. 94.
    Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, et al. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro Oncol. 2013;15:650–5.  https://doi.org/10.1093/neuonc/not020.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot. 2009;67:S37–42.  https://doi.org/10.1016/j.apradiso.2009.03.103.CrossRefPubMedGoogle Scholar
  96. 96.
    Yamamoto T, Nakai K, Nariai T, Kumada H, Okumura T, Mizumoto M, et al. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation. Appl Radiat Isot. 2011;69:1817–8.  https://doi.org/10.1016/j.apradiso.2011.02.013.CrossRefPubMedGoogle Scholar
  97. 97.
    Watanabe Y, Kurihara H, Itami J, Sasaki R, Arai Y, Sugimura K. Relationship between the uptake of 18F-borono-l-phenylalanine and l-[methyl-11C]methionine in head and neck tumors and normal organs. Radiat Oncol. 2017;12:17.  https://doi.org/10.1186/s13014-017-0763-6.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Tani H, Kurihara H, Hiroi K, Honda N, Yoshimoto M, Kono Y, et al. Correlation of 18F-BPA and 18F-FDG uptake in head and neck cancers. Radiother Oncol. 2014;113:193–7.  https://doi.org/10.1016/j.radonc.2014.11.001.CrossRefPubMedGoogle Scholar
  99. 99.
    Kobayashi K, Kurihara H, Watanabe Y, Murakami N, Inaba K, Nakamura S, et al. In vivo spatial correlation of 18F-BPA and 18F-FDG uptake in head and neck cancer. Appl Radiat Isot. 2016;115:138–46.  https://doi.org/10.1016/j.apradiso.2016.05.026.CrossRefPubMedGoogle Scholar
  100. 100.
    Miyashita M, Miyatake S, Imahori Y, Yokoyama K, Kawabata S, Kajimoto Y, et al. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol. 2008;89:239–46.  https://doi.org/10.1007/s11060-008-9621-6.CrossRefPubMedGoogle Scholar
  101. 101.
    Miyatake S, Kawabata S, Nonoguchi N, Yokoyama K, Kuroiwa T, Ono K. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol. 2009;11:430–6.  https://doi.org/10.1215/15228517-2008-107.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K, et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res. 2009;50:51–60.CrossRefPubMedGoogle Scholar
  103. 103.
    Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol. 2014;9:6.  https://doi.org/10.1186/1748-717X-9-6.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003;98:1056–64.  https://doi.org/10.3171/jns.2003.98.5.1056.CrossRefPubMedGoogle Scholar
  105. 105.
    Beshr R, Isohashi K, Watabe T, Naka S, Horitsugi G, Romanov V, et al. Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [18F]fluoro-borono-phenylalanine PET/CT. Ann Nucl Med. 2018;32:702–8.  https://doi.org/10.1007/s12149-018-1296-2.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Southern TOHOKU Drug Discovery and Cyclotron Research CenterSouthern TOHOKU Research Institute for NeuroscienceKoriyamaJapan
  2. 2.Department of Biofunctional ImagingFukushima Medical UniversityFukushimaJapan

Personalised recommendations